October 3, 2025Lab on a ChipOpen Access

Evaluating Anti-Sickling Therapies for Sickle Cell Disease: A Microfluidic Assay for Red Blood Cell-Mediated Microvascular Occlusion Under Hypoxia

View Full Paper

Ask AI

Bookmark

Authors

ZSZoe SekyondaCase Western Reserve University YDYong DuState Key Laboratory of Pollution Control and Resource Reuse SOSolomon OshabaheebwaCase Western Reserve University

Discussion

Member takes

Implication

This analysis demonstrates the impact of therapies on red blood cell behavior under hypoxia in sickle cell disease, suggesting potential advancements.

Key Points

The microfluidic assay evaluates anti-sickling therapies' effects on RBCs under hypoxia, revealing treatment impacts.
Key evidence shows that therapies may enhance RBC deformability and reduce occlusion in microvascular systems.
This study employs a microfluidic assay to assess RBC behavior in a controlled hypoxic environment for accurate analysis.
These findings highlight the importance of innovative assays in developing effective treatments for sickle cell disease.

Cite This Study

Sekyonda et al. (2025) studied this question.

synapsesocial.com/papers/68e02f46f0e39f13e7fa2c07 https://doi.org/10.1039/d5lc00264h

View Full Paper

Ask AI

Bookmark

Implication

This analysis demonstrates the impact of therapies on red blood cell behavior under hypoxia in sickle cell disease, suggesting potential advancements.

Evaluating Anti-Sickling Therapies for Sickle Cell Disease: A Microfluidic Assay for Red Blood Cell-Mediated Microvascular Occlusion Under Hypoxia

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluating Anti-Sickling Therapies for Sickle Cell Disease: A Microfluidic Assay for Red Blood Cell-Mediated Microvascular Occlusion Under Hypoxia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider